{"id":63658,"date":"2024-08-13T18:00:00","date_gmt":"2024-08-13T16:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/"},"modified":"2024-08-13T18:00:00","modified_gmt":"2024-08-13T16:00:00","slug":"ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/","title":{"rendered":"IPSEN &#8211; Buy-back programme &#8211; Art 5 of MAR &#8211; Week 32 &#8211; 2024"},"content":{"rendered":"<p><u>Aggregated<\/u> <u>presentation<\/u> <u>by<\/u> <u>day<\/u> <u>and<\/u> <u>by<\/u> <u>market<\/u><\/p>\n<table style=\"border-collapse: collapse;width:677pt;border-collapse:collapse\">\n<tr>\n<td colspan=\"7\" style=\"width:902.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle\"><strong>Purchases of own shares from August 5th to August 7th, 2024<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:174.67px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:112.00px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:165.34px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:130.67px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:106.67px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:102.67px;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\"><strong>Name of the Issuer<\/strong><\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle\"><strong>Identity code of the Issuer<\/strong><\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle\"><strong>Day of the transaction<\/strong><\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle\"><strong>Identity code of the financial instrument<\/strong><\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle\"><strong>Total daily volume (in number of shares)<\/strong><\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle\"><strong>Daily weighted average purchase price of the shares<\/strong><\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle\"><strong>Market (MIC Code)<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\">IPSEN<\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">549300M6SGDPB4Z94P11<\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle;vertical-align: bottom\">05\/08\/2024<\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle;vertical-align: bottom\">FR0010259150<\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">9 021<\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">103,0295<\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">XPAR<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\">IPSEN<\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">549300M6SGDPB4Z94P11<\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle;vertical-align: bottom\">05\/08\/2024<\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle;vertical-align: bottom\">FR0010259150<\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">4 119<\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">102,9704<\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">CEUX<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\">IPSEN<\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">549300M6SGDPB4Z94P11<\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle;vertical-align: bottom\">05\/08\/2024<\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle;vertical-align: bottom\">FR0010259150<\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">727<\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">102,9999<\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">TQEX<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\">IPSEN<\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">549300M6SGDPB4Z94P11<\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle;vertical-align: bottom\">05\/08\/2024<\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle;vertical-align: bottom\">FR0010259150<\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">989<\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">103,0782<\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">AQEU<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\">IPSEN<\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">549300M6SGDPB4Z94P11<\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle;vertical-align: bottom\">06\/08\/2024<\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle;vertical-align: bottom\">FR0010259150<\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">7 492<\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">102,8158<\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">XPAR<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\">IPSEN<\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">549300M6SGDPB4Z94P11<\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle;vertical-align: bottom\">06\/08\/2024<\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle;vertical-align: bottom\">FR0010259150<\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">2 387<\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">102,8565<\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">CEUX<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\">IPSEN<\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">549300M6SGDPB4Z94P11<\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle;vertical-align: bottom\">06\/08\/2024<\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle;vertical-align: bottom\">FR0010259150<\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">455<\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">102,7316<\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">TQEX<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\">IPSEN<\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">549300M6SGDPB4Z94P11<\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle;vertical-align: bottom\">06\/08\/2024<\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle;vertical-align: bottom\">FR0010259150<\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">634<\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">102,6875<\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">AQEU<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\">IPSEN<\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">549300M6SGDPB4Z94P11<\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle;vertical-align: bottom\">07\/08\/2024<\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle;vertical-align: bottom\">FR0010259150<\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">2 153<\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">103,0974<\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">XPAR<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;text-align: center;vertical-align: middle\">IPSEN<\/td>\n<td style=\"width:174.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">549300M6SGDPB4Z94P11<\/td>\n<td style=\"width:112.00px;text-align: center;vertical-align: middle;vertical-align: bottom\">07\/08\/2024<\/td>\n<td style=\"width:165.34px;text-align: center;vertical-align: middle;vertical-align: bottom\">FR0010259150<\/td>\n<td style=\"width:130.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">1 000<\/td>\n<td style=\"width:106.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">103,1034<\/td>\n<td style=\"width:102.67px;text-align: center;vertical-align: middle;vertical-align: bottom\">CEUX<\/td>\n<\/tr>\n<tr>\n<td style=\"width:110.67px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:174.67px;border-top: solid black 1pt;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"width:112.00px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:165.34px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\"><strong>TOTAL<\/strong><\/td>\n<td style=\"width:130.67px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\"><strong>28 977 <\/strong><\/td>\n<td style=\"width:106.67px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\"><strong>102,9480<\/strong><\/td>\n<td style=\"width:102.67px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Attachment<\/strong>\n<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=MGkli9Q6f3b6LX1KqfXKQ1invKSPSqB0HL7kI2-v5rmLbarn5XdAdMp12XGjyPdf-K07fEPSmqwFxjUYTbNBbo44qbDIDlL70_qIyQfd8Z5MtgPuVAEcXrIAIWVIhqU4mYsS7SpLMPnwHMUzUotyyq8i2qV8pKJPte-sd1nFWeiCusEglP0scaYRSpZwuUBZvKUXiTBZysOxEHd2o5otmEhRlqegrdNjFbNEYYO2iEc=\" title=\"EN_IPSEN - Buy-back programme - Art 5 of MAR - Week 32_2024\" rel=\"nofollow noopener\">EN_IPSEN &#8211; Buy-back programme &#8211; Art 5 of MAR &#8211; Week 32_2024<\/a>\n      <\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1771],"tags":[],"class_list":["post-63658","press_release","type-press_release","status-publish","hentry","category-regulated-info","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"IPSEN &#8211; Buy-back programme &#8211; Art 5 of MAR &#8211; Week 32 &#8211; 2024\",\"datePublished\":\"2024-08-13T16:00:00+00:00\",\"dateModified\":\"2024-08-13T16:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/\"},\"wordCount\":148,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"articleSection\":[\"Regulated Information\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/\",\"url\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/\",\"name\":\"IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"datePublished\":\"2024-08-13T16:00:00+00:00\",\"dateModified\":\"2024-08-13T16:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IPSEN &#8211; Buy-back programme &#8211; Art 5 of MAR &#8211; Week 32 &#8211; 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/#website\",\"url\":\"https:\/\/www.ipsen.com\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/","og_locale":"en_US","og_type":"article","og_title":"IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024","og_url":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/","og_site_name":"Global","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"IPSEN &#8211; Buy-back programme &#8211; Art 5 of MAR &#8211; Week 32 &#8211; 2024","datePublished":"2024-08-13T16:00:00+00:00","dateModified":"2024-08-13T16:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/"},"wordCount":148,"publisher":{"@id":"https:\/\/www.ipsen.com\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","articleSection":["Regulated Information"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/","url":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/","name":"IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024","isPartOf":{"@id":"https:\/\/www.ipsen.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","datePublished":"2024-08-13T16:00:00+00:00","dateModified":"2024-08-13T16:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MmZmZDdhMjctZWM1YS00MzJmLWIxOGMtOWZjMzUzMTRlZTc0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-buy-back-programme-art-5-of-mar-week-32-2024-2929469\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/"},{"@type":"ListItem","position":2,"name":"IPSEN &#8211; Buy-back programme &#8211; Art 5 of MAR &#8211; Week 32 &#8211; 2024"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/#website","url":"https:\/\/www.ipsen.com\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release\/63658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release\/63658\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/media?parent=63658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/categories?post=63658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/tags?post=63658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}